Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells - PubMed (original) (raw)

Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells

Markey C McNutt et al. J Biol Chem. 2009.

Abstract

PCSK9 is a secreted protein that degrades low density lipoprotein receptors (LDLRs) in liver by binding to the epidermal growth factor-like repeat A (EGF-A) domain of the LDLR. It is not known whether PCSK9 causes degradation of LDLRs within the secretory pathway or following secretion and reuptake via endocytosis. Here we show that a mutation in the LDLR EGF-A domain associated with familial hypercholesterolemia, H306Y, results in increased sensitivity to exogenous PCSK9-mediated cellular degradation because of enhanced PCSK9 binding affinity. The crystal structure of the PCSK9-EGF-A(H306Y) complex shows that Tyr-306 forms a hydrogen bond with Asp-374 in PCSK9 at neutral pH, which strengthens the interaction with PCSK9. To block secreted PCSK9 activity, LDLR (H306Y) subfragments were added to the medium of HepG2 cells stably overexpressing wild-type PCSK9 or gain-of-function PCSK9 mutants associated with hypercholesterolemia (D374Y or S127R). These subfragments blocked secreted PCSK9 binding to cell surface LDLRs and resulted in the recovery of LDLR levels to those of control cells. We conclude that PCSK9 acts primarily as a secreted factor to cause LDLR degradation. These studies support the concept that pharmacological inhibition of the PCSK9-LDLR interaction extracellularly will increase hepatic LDLR expression and lower plasma low density lipoprotein levels.

PubMed Disclaimer

Figures

FIGURE 1.

FIGURE 1.

Increased binding and degradation of LDLR(H306Y) by PCSK9. A, competition binding of EGF-AB and EGF-AB(H306Y) to PCSK9. Purified PCSK9 was prebound to slot-blotted anti-FLAG M2 monoclonal antibody (mAb). Blots were incubated for 90 min with 0.1 μg/ml infrared dye (DyLight800)-labeled LDLR-ECD at pH 7.4 in the presence of increasing concentrations of unlabeled EGF-AB (closed circles) or EGF-AB(H306Y) (open circles), and bound fluorophore-labeled LDLR was detected and quantified. B, HuH7 cells transiently expressing LDLR-WT or LDLR(H306Y) were cultured in sterol-supplemented medium (see “Experimental Procedures”) and treated for 1 h with the indicated amount of purified FLAG-tagged PCSK9. Cells were lysed, and cell extracts were subjected to SDS-PAGE and immunoblot analysis as described under “Experimental Procedures.” Internalized PCSK9 was detected with anti-FLAG M2 mAb. LDLR was detected with an anti-LDLR mAb (HL-1). TFR was detected as a control for equal protein loading. C, HuH7 cells transfected as in B were treated with the indicated amount of PCSK9 for 4 h. Following biotinylation, isolated cell surface protein lysates were subjected to SDS-PAGE and immunoblot analysis. LDLR and TFR were detected as in B. Secondary detection used an infrared dye (IRDye800)-labeled antibody. Blots were visualized and quantified using the LI-COR Odyssey infrared imaging system. LDLR levels were normalized to TFR expression. For these and subsequent data, results shown are from representative experiments repeated at least three times with similar results. Vec, vector.

FIGURE 2.

FIGURE 2.

Structure of the PCSK9-EGF-A complex. The sigmaA weighted 2_Fo_ - Fc electron density map contoured at 1σ shows the conformational change that occurs upon protonation of His-306. EGF-A and PCSK9 are represented as a stick model. Residues involved in the pH-dependent conformational change are colored according to element type as follows: nitrogen, blue; oxygen,red; EGF-A carbon, yellow; PCSK9 carbon, green. All other residues are colored gray. A, at acidic pH, His-306 of EGF-A forms a salt bridge with Asp-374 of PCSK9. B, at neutral pH, His-306 of EGF-A forms an intramolecular hydrogen bond with Ser-305. C, FH mutation H306Y of EGF-A is able to form a hydrogen bond with Asp-374 of PCSK9 at neutral pH.

FIGURE 3.

FIGURE 3.

EGF-AB(H306Y) blocks uptake of PCSK9 in HuH7 cells. HuH7 cells were treated 30 min with 5 μg/ml purified full-length FLAG-tagged PCSK9 alone or in combination with 5 μ

m

EGF-AB(H306Y) blocking peptide or EGF-AB(L318A) negative-control peptide. A–D, cells were immunostained for PCSK9 (green) and nuclear stained with 4′,6-diamidino-2-phenylindole (magenta) as described under “Experimental Procedures.” E, cells were lysed and subjected to SDS-PAGE and immunoblotting for FLAG-tagged PCSK9 as described in the legend to Fig. 1_B_. Actin was detected as a control for equal protein loading. PCSK9 and actin levels were visualized and quantified using an IRDye800-labeled secondary antibody and the LI-COR Odyssey infrared imaging system. PCSK9 levels were normalized to actin expression.

FIGURE 4.

FIGURE 4.

EGF-AB(H306Y) treatment restores LDLR numbers in PCSK9 overexpressing cells. HepG2 cells stably overexpressing empty vector or wild-type PCSK9 (WT) were cultured in sterol-depleting medium (see “Experimental Procedures”) and treated for 18 h with 5 μ

m

EGF-AB(H306Y) or negative-control EGF-AB(L318A) peptides.A, cell surface proteins were isolated following biotinylation, and whole cell and cell surface protein extracts were subjected to SDS-PAGE and immunoblot analysis for LDLR. LDLR and TFR levels were visualized as described in the legend to Fig. 1_C_ . B, LDLR bands in A were quantified using the LI-COR Odyssey infrared imaging system. Values were normalized to TFR and graphed relative to untreated vector-transfected control cells.

FIGURE 5.

FIGURE 5.

EGF-AB(H306Y) treatment restores LDLR number and function in gain-of-function PCSK9 overexpressing cell lines. A and_B,_ HepG2 cells stably overexpressing empty vector, PCSK9(S127R), or PCSK9(D374Y) were cultured in sterol-depleting medium (see “Experimental Procedures”) and treated for 18 h with 5 μ

m

EGF-AB(H306Y) or negative-control EGF-AB(L318A) peptides. LDLR and TFR levels in cell surface and whole cell protein extracts were visualized and quantified as described in the legend to Fig. 4. C, empty vector, PCSK9-WT, PCSK9(S127R), or PCSK9(D374Y) overexpressing cells were treated for 18 h with the indicated concentration of EGF-AB(H306Y) or EGF-AB(L318A) and then incubated for 2 h with 100 μg/ml DiI-LDL. Cells were trypsinized, and the mean fluorescence intensity of each sample was measured by flow cytometry. Six replicate samples were used per condition. * indicates a statistical difference between columns with significance, p < 0.05, by one-way analysis of variance and post-test pairwise comparison using Tukey's method;**, p < 0.005; ***, p < 0.001.

References

    1. Goldstein, J. L., Brown, M. S., Anderson, R. G., Russell, D. W., and Schneider, W. J. (1985) Annu. Rev. Cell Biol. 1 1-39 - PubMed
    1. Hobbs, H. H., Russell, D. W., Brown, M. S., and Goldstein, J. L. (1990) Annu. Rev. Genet. 24 133-170 - PubMed
    1. Innerarity, T. L., Mahley, R. W., Weisgraber, K. H., Bersot, T. P., Krauss, R. M., Vega, G. L., Grundy, S. M., Friedl, W., Davignon, J., and McCarthy, B. J. (1990) J. Lipid Res. 31 1337-1349 - PubMed
    1. Abifadel, M., Varret, M., Rabes, J. P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., Derre, A., Villeger, L., Farnier, M., Beucler, I., Bruckert, E., Chambaz, J., Chanu, B., Lecerf, J. M., Luc, G., Moulin, P., Weissenbach, J., Prat, A., Krempf, M., Junien, C., Seidah, N. G., and Boileau, C. (2003) Nat. Genet. 34 154-156 - PubMed
    1. Maxwell, K. N., and Breslow, J. L. (2004) Proc. Natl. Acad. Sci. U. S. A. 101 7100-7105 - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources